Was Dr. Bunn Insensitive Or Just Efficient? FDA Imbroglio Points To Larger Problems
In Brief: ASTRO Officers Named; AACR Fellowships Available; NRC Won’t Revoke NIH License
FDA Likely To Change Procedures For Patient Interaction, Official Says
RPR Grant To NABCO Does Not Support Advocacy, Firm Says
ODAC Chairman: Time Was Tight For Meeting
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









